Group 1 - The core decision of the board meeting was to conclude certain fundraising projects and permanently allocate the surplus funds to working capital [3][18] - The board meeting was held on December 17, 2025, with all seven directors present, and the decision was unanimously approved [2][4] - The surplus amount from the concluded projects is 36.9774 million yuan, which will be used to enhance the efficiency of fund utilization and support daily operations [9][16] Group 2 - The concluded fundraising projects include the Rehabilitation Equipment Assembly and Debugging Project and the Information Technology Construction Project [9][11] - The total fundraising raised was approximately 1.155 billion yuan, with a net amount of about 1.063 billion yuan after deducting issuance costs [10] - The surplus funds were generated due to effective cost control and management during the project implementation, leading to lower expenditures than initially planned [13][14] Group 3 - The decision to use surplus funds for working capital is aimed at optimizing resource allocation and enhancing operational efficiency, aligning with the company's long-term development strategy [16][17] - The audit committee and sponsor institution both support the decision, confirming it does not harm the interests of shareholders and complies with relevant regulations [17][19]
南京伟思医疗科技股份有限公司第四届董事会第七次会议决议公告